The purpose of the ABSL3/BSL3 microbiology core (Core B) is to provide a high quality, uniform source of Franciseiia tularensis {Ft), avoid duplication of work, and provide a shared resource for all investigators. The rationale is that a centralized facility run by trained technicians will be more able to consistently generate reliable reagents for all components of the Program Project. The primary objectives of Core B are to ensure proper maintenance and supply of bacterial stocks;to provide ABSL3 animal husbandry and maintenance of the ABSL3/BSL3 facility;and to provide training and oversight to individuals working in the ABSL3/BSL3 suite. Additionally, in light of our recent observations that variation in the growth media used for propagating Ft LVS exerts profound effects on bacterial gene expression and the host's response to these bacteria. Core B will also determine the growth conditions for Ft SchuS4 which produce a bacterial phenotype similar to that of infection-derived bacteria. The rationale behind these efforts is that Ff-mAb complexes generated with bacteria displaying the infection-derived phenotype will likelv induce a more effective immune response because it is tailored toward the bacteria prosecuting the infection. Results from these efforts will also dictate which media is used by the core for the production of bacterial stocks provided to the subprojects. To achieve these goals, Core B will: 1. Maintain Ft SchuS4 stock cultures. 2. Provide animal husbandry and BSL3 facility maintenance. 3. Provide training and oversight. 4. Determine the bacterial growth medium which yields Ft with a phenotype most similar to that of infection-derived bacteria.

Public Health Relevance

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LR-M (S1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albany Medical College
United States
Zip Code
Dixon, Ann M; Drake, Lisa; Hughes, Kelly T et al. (2014) Differential transmembrane domain GXXXG motif pairing impacts major histocompatibility complex (MHC) class II structure. J Biol Chem 289:11695-703
Pham, Giang H; Iglesias, Bibiana V; Gosselin, Edmund J (2014) Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells. Vaccine 32:5212-20
Furuya, Yoichi; Wijesundara, Danushka K; Neeman, Teresa et al. (2014) Use and misuse of statistical significance in survival analyses. MBio 5:e00904-14
Ma, Zhuo; Banik, Sukalyani; Rane, Harshita et al. (2014) EmrA1 membrane fusion protein of Francisella tularensis LVS is required for resistance to oxidative stress, intramacrophage survival and virulence in mice. Mol Microbiol 91:976-95
Singh, Anju; Rahman, Tabassum; Malik, Meenakshi et al. (2013) Discordant results obtained with Francisella tularensis during in vitro and in vivo immunological studies are attributable to compromised bacterial structural integrity. PLoS One 8:e58513
Furuya, Yoichi; Kirimanjeswara, Girish S; Roberts, Sean et al. (2013) Increased susceptibility of IgA-deficient mice to pulmonary Francisella tularensis live vaccine strain infection. Infect Immun 81:3434-41
Mahawar, Manish; Rabadi, Seham M; Banik, Sukalyani et al. (2013) Identification of a live attenuated vaccine candidate for tularemia prophylaxis. PLoS One 8:e61539
Metzger, Dennis W; Salmon, Sharon L; Kirimanjeswara, Girish (2013) Differing effects of interleukin-10 on cutaneous and pulmonary Francisella tularensis live vaccine strain infection. Infect Immun 81:2022-7
Iglesias, Bibiana V; Bitsaktsis, Constantine; Pham, Giang et al. (2013) Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen. Immunol Cell Biol 91:139-48
Dotson, Rachel J; Rabadi, Seham M; Westcott, Elizabeth L et al. (2013) Repression of inflammasome by Francisella tularensis during early stages of infection. J Biol Chem 288:23844-57

Showing the most recent 10 out of 38 publications